Pharmacogenetics

British Medical Journal

Volumn 320, Issue 7240, 2000, Pages 987-990

  Wolf, C Roland ^a   Smith, Gillian ^a   Smith, Robert L ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; THIOPURINE METHYLTRANSFERASE;

DRUG TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME; GENOTYPE; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SHORT SURVEY; DRUG HYPERSENSITIVITY; FORECASTING; GENETICS; REVIEW;

DRUG HYPERSENSITIVITY; FORECASTING; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0034621009     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (13)

1. 1 The cost of adverse drug reactions [editorial]. Adverse Drug React Toxicol Rev 1997;16:75-8.
2. 2 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-5.
3. 3 Vogel F. Moderne probleme der Humangenetik. Ergeb Inn Med Kinderheild 1959;12:52-125.
4. 4 Weber WW. Pharmacogenetics. Oxford: Oxford University Press, 1997.
5. 5 Wolf CR, Smith G. Pharmacogenetics. Br Med Bull 1999;55:366-86.
6. 6 Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.
7. 7 Johansson I, Lundquist F., Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci (USA) 1993;90:11825-9.
8. 8 Bertilsson L, Dahl ML, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational mega-prescribing in ultrarapid hydroxylators of debrisoquin. Lancet 1993;341:363.
9. 9 Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
10. 10 Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Sheutz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996;6:279-90.
11. 11 ABPI compendium of data sheets and summaries of product characteristics 1999-2000. London: Datapharm, 1999.
12. 12 Physicians' Desk Reference 2000. 54th ed. Montvale NJ: Medical Economics, 1999.
13. 13 Chou WH, Yan F-X, de Leon J, Barnhill J, Rogers T, Cronin M, et al. An extension of a pilot study: impact from the cytochrome P450-2D6 (CYP2D6) polymorphism on outcome and costs in severe mental illness. J Clin Psychopharmacol (in press).